XGN · Exagen Inc.

Current Thesis

Exagen's thesis is that its August revenue beat and improving test pricing sustain a re-rating toward BTIG's $9 target; a weekly close below $6.36 invalidates that price case. The operating evidence remains the 2026-08-04 results: quarterly revenue of $19.941 million and increased full-year revenue guidance of $72–75 million. Exagen results.

The measured change since the September 5 note is price strength: the adjusted close advanced from $7.58 on 2026-09-04 to $8.41 on 2026-09-18. Coverage also resumed: TipRanks reports a B. Riley coverage transfer on 2026-09-11 with its $12 target unchanged. That corrects the earlier description of stopped coverage, but supplies no higher valuation target. Reported analyst action.

The narrative is maturing — this is an inference from the unchanged September 11 target and the September 17 publication of the existing August earnings-call transcript. Neither item establishes a new operating acceleration. The lifecycle assessment would change if fresh results improved the August guidance and the market closed above the September 18 reference close. Transcript publication.

Bullish and bearish views on Exagen Inc.

The model's bull view on Exagen Inc. (XGN), in brief: Pricing and volume improved together. Exagen's 2026-08-04 release reported an AVISE CTD trailing-twelve-month average selling price (ASP) of $446 per test, up 4% year over year, alongside 11% test-volume growth. Company results. Operating losses narrowed materially. For Q2 2026… The bear view: Adjusted profitability leaves a gap. Exagen reported a Q2 2026 net loss under generally accepted accounting principles (GAAP) of $3.2 million and approximately $24.6 million of cash at 2026-06-30. Its adjusted EBITDA calculation excludes stock compensation and other items.… Both cases follow in full.

Bull Case

• Pricing and volume improved together. Exagen's 2026-08-04 release reported an AVISE CTD trailing-twelve-month average selling price (ASP) of $446 per test, up 4% year over year, alongside 11% test-volume growth. Company results.
• Operating losses narrowed materially. For Q2 2026, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) showed a $0.1 million loss, compared with a $1.7 million loss a year earlier; gross margin reached 61.3%. These are measured improvements, not evidence that cash breakeven has arrived. Company results.
• Analyst valuation support persisted. B. Riley's reported 2026-09-11 action retained a $12 target, following the August reset. It supports continuity of that analyst's view rather than a fresh target increase. Reported analyst action.

Bear Case

• Adjusted profitability leaves a gap. Exagen reported a Q2 2026 net loss under generally accepted accounting principles (GAAP) of $3.2 million and approximately $24.6 million of cash at 2026-06-30. Its adjusted EBITDA calculation excludes stock compensation and other items. Company results and reconciliation.
• One assay dominates revenue. The August 4 results attributed $17.7 million of Q2 2026 revenue to AVISE CTD.
• Recent publication adds no quarter. Benzinga's 2026-09-17 transcript concerns the quarter ended 2026-06-30. Its publication date does not establish a September earnings beat or updated guidance. Transcript.

Setup & Price Structure

The 2026-09-18 adjusted reference close was $8.41, with a three-month price increase of 90.3%. The 14-day relative strength index (RSI) measured 68.2, versus 65.5 on 2026-09-04. Price remained 29.7% below the adjusted 52-week high of $11.96, according to the supplied September 18 daily-bar snapshot. These observations establish stronger price momentum; they do not identify who supplied demand.

The price case is fulfilled by a weekly close at or above BTIG's $9 target, reported on 2026-08-05, before a weekly close below $6.36. The latter is the August 4 gap-session reference retained from the prior published analysis, not the pre-earnings close. BTIG target history.

The positioning evidence is limited. Analyst revisions clustered on 2026-08-05, followed by B. Riley's unchanged September 11 target. The September 2 Form 4 described the CFO's September 1 disposal as issuer-mandated tax withholding on restricted stock unit vesting, which does not establish discretionary selling. No current retail-participation series, short-interest series or moving-average measurement is supplied; crowding cannot be established from the price gain alone.

Catalyst Calendar (next 30 days)

• ~2026-09-30, estimated — myositis training checkpoint. On the August 4 call, management placed sales-force training at the end of Q3 ahead of the planned early-2027 launch. This is an operational timetable, with no scheduled public disclosure attached; later confirmation of a delay would weaken the product-expansion case. Call transcript published September 17.
• ~2026-11-03, estimated — Q3 results. This later event is the operating test for the thesis: updated ASP and full-year guidance can confirm or contradict the August improvement. MarketBeat lists November 3 as estimated and explicitly states that Exagen has not confirmed the date. Earnings calendar.

As checked on 2026-09-20, Exagen's investor-relations page lists no upcoming event. No company-confirmed disclosure catalyst has been established within the next 30 days. Exagen investor relations.

What Would Change Our Mind

Loss of the August earnings-session reference would end the price thesis: a weekly close below $6.36 is the observable failure condition. Separately, the next results would contradict the operating case if management reduced its August 4 full-year revenue guidance of $72–75 million or reported trailing-twelve-month AVISE CTD ASP at or below $446 per test. Unchanged revenue guidance alone would not demonstrate deterioration; it would leave the existing range intact.

Correlation Notes

This remains a single-name diagnostics setup. The supplied 2026-09-18 snapshot establishes Exagen's three-month price increase but includes no matched sector or benchmark return series. It cannot support a measured correlation claim or establish that a group move explains the advance. The company-specific mechanism is the pricing and volume improvement reported on August 4; attribution of subsequent share-price strength to that mechanism remains an inference.